Antivirals panel to discuss hepatitis C trials
Executive Summary
FDA's Antiviral Drugs Advisory Committee will meet Oct. 19-20 to discuss issues of clinical trial design pertaining to the development of chronic hepatitis C drugs, including the identification of appropriate control arms, study populations, endpoints and long-term follow-up. The meeting is being called "in response to the growing number of products in development for this indication." Novartis and Human Genome Sciences, Vertex Pharmaceuticals and Schering-Plough are currently developing hepatitis C therapies. The two-day meeting will be held at the Hilton in Silver Spring, Md., from 8 a.m. until 4 p.m. each day. [Editor's note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.